Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG)

NCT01316874 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT01316874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01316874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG)
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 1993
Completion date
April 30, 1997
Enrollment
90 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, carcinoma in situ